Open AccessPharmacological therapy used in the elimination ofHelicobacter pyloriinfection: A Review
Author(s) -
Ariolana A dos Santos,
Adriana Andrade Carvalho
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i1.139
Subject(s) - regimen , helicobacter pylori , levofloxacin , clarithromycin , medicine , helicobacter pylori infection , pharmacotherapy , concomitant , antibiotics , drug resistance , drug , pharmacology , gastroenterology , biology , microbiology and biotechnology
The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.